IL-6
4 articles
Computational & AIJournal of Computer-Aided Molecular Design (Springer Nature)
Random forest screen yields GSK-3β hit with cellular anti-inflammatory activity
- A random forest trained on literature GSK-3β inhibitors served as a first-pass filter for a commercial library, followed by ADMET filtering, docking and molecular dynamics.
- Two selected compounds showed only moderate enzymatic inhibition.
- The better one, a non-classical hindered aromatic ester, lowered TNF-α and IL-6 in cells with low cytotoxicity; the authors attribute this to lipophilicity and cellular accumulation, which was not directly tested.
Two tested compounds with only moderate enzyme inhibition is a modest return for a screen, and I'd want the denominator: how many random picks from the same filtered library would hit at that level? Without a docking-only or similarity-search baseline, the forest's contribution is unproven. Since the cell effect is unexplained, a counter-screen against other kinases would be my next step.
Paper: Journal of Computer-Aided Molecular Design (Springer Nature) ↗
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Indolizine cap group delivers a selective HDAC6 inhibitor that calms neuronal inflammation
- The authors used an indolizine as a new cap group within the standard HDAC pharmacophore and made a 13-member series.
- SAR showed that decorating the cap group is key to balancing potency and isoform selectivity; indostat (5g) emerged as the best compound, with balanced solubility, stability and lipophilicity.
- In hippocampal neurons stimulated with poly(I:C), indostat lowered IL-6 secretion and normalized the rise in HDAC6 activity.
- Anti-inflammatory effect matched pan-HDAC inhibitor SAHA, with better cellular tolerability.
Matching SAHA on IL-6 is a low bar for a selective HDAC6 compound; I'd add a tubastatin-type benchmark and HDAC6 knockdown to show the effect is on-target. Indolizine is an easy cap to decorate, but electron-rich ring systems can be oxidation-prone, so I'd check oxidative and photostability early.
Industry NewsNovo NordiskSTAT News
Novo's Ziltivekimab Fails ZEUS, but Cardiologists Keep Chasing Inflammation
- Full ZEUS results were discussed at the AHA meeting. The once-monthly IL-6 antibody did not cut major cardiovascular events in patients with atherosclerotic disease, kidney disease and elevated inflammation, even though it lowered IL-6 and hsCRP as intended.
- Serious infections were more frequent on drug, Novo is taking a non-cash impairment, and the heart failure (HERMES) and post-heart-attack (ARTEMIS) trials continue, reading out in the first half of 2027.
A clean target-engagement miss is the worst case for IL-6: the biomarker moved and outcomes did not, which undercuts hsCRP as a surrogate for patient selection. Colchicine and Novartis's IL-1β precedent keep the inflammation thesis alive, but HERMES and ARTEMIS now carry the whole franchise, and an infection signal is a hard thing to net against a modest benefit.
Industry NewsNovo NordiskEndpoints News
Novo Nordisk halts two more ziltivekimab heart trials on futility finding
- Novo Nordisk is stopping two Phase 3 trials, HERMES and ATHENA, of ziltivekimab early after a data monitoring committee flagged futility.
- Ziltivekimab is an antibody that targets interleukin-6 (IL-6), an inflammatory cytokine, and the trials were testing it in heart failure patients with inflammation.
- The committee concluded neither trial was likely to produce a different result from the earlier Phase 3 ZEUS trial, which missed its cardiovascular endpoint in July.
- HERMES tracked time to cardiovascular death or heart failure-related hospitalization/urgent visits; ATHENA measured broader heart failure outcomes including quality of life.
- Novo Nordisk is continuing a separate Phase 3 trial, ARTEMIS, testing ziltivekimab as an acute post-heart-attack treatment, with a readout expected in the first half of 2027.
- The repeated failures raise doubts about IL-6 inhibition as a viable cardiovascular treatment strategy.
Three strikes on cardiovascular endpoints now — ZEUS in July, HERMES and ATHENA today — and Novo isn't spinning this as a design problem anymore; the DMC futility call is about as clear a kill signal as you get. Sunk cost here isn't trivial: ziltivekimab was Novo's flagship diversification bet outside GLP-1s, and this guts the broader inflammation-in-CV thesis that Novartis also struggled to validate with canakinumab post-CANTOS. IL-6 as a druggable node for heart failure now looks structurally shaky, not just underpowered. ARTEMIS surviving to 2027 reads less like conviction and more like sunk-cost inertia — acute post-MI biology differs, but a quiet wind-down before readout wouldn't surprise me if enrollment softens. Zoom out and this underscores just how thin Novo's non-GLP-1 pipeline really is, right as obesity/diabetes competition intensifies.